News Release Feb 17, 2025 Others Please be aware of suspicious e-mails purporting to be from our company's employees and directors Aug 27, 2024 Others Please be aware of suspicious e-mails purporting to be from our company's employees and directors Jun 10, 2024 Management On the occasion of our 125th anniversary, our corporate slogan and logo design have been renewed. Apr 16, 2024 Products/BusinessR&D Lab & office opened at "Nakanoshima Qross (Future Medical International Center)" Feb 8, 2024 Products/Business ROHTO Pharmaceutical Launches an AI Project Using Microsoft AI Co-Innovation Lab Feb 1, 2024 Management Strategic Business Partnership between ROHTO MediLuxe Europe and EMA AESTHETICS Oct 26, 2023 Management ROHTO Pharmaceutical Co., Ltd. Investing to Develop Novel Solution for Urinary Incontinence Symptoms, Venturing into New Values, Products, and Businesses in the Healthcare Sector. May 12, 2023 Sustainability Goals for 2030 in non-financial areas (environment/society) "Sustainability Goals 2030" May 12, 2023 Sustainability Establishment of Sustainability Targets 2030 (environmental and social axis) May 10, 2023 Management Fujita Academy and Rohto Pharmaceutical Co., Ltd. establish a joint venture and enter the real world data business. May 10, 2023 Management Fujita Gakuen and ROHTO Pharmaceutical Co., Ltd. established a joint venture and entered the real-world data business. Sep 30, 2022 R&D Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan Sep 27, 2022 Management ROHTO Pharmaceutical's Mother Plant, Ueno Techno Center, Commences Operations of New Facility Sep 26, 2022 Sustainability Announcement Regarding the Acquisition of Full Ownership of Naris Cosmetics Vietnam Co., Ltd. by ROHTO Mentholatum (Vietnam) Co., Ltd. Jun 22, 2022 Management Announcement of Joint Venture Establishment for Advancing Regenerative Medicine Business in China Mar 28, 2022 R&D Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202" Mar 24, 2022 Management Participation in the Osaka Pavilion at the 2025 World Exposition in Japan (Osaka and Kansai Exposition) Sep 7, 2021 ManagementR&D Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information Aug 31, 2021 Management Completion of Share Acquisition of Amato Pharmaceutical Products, Ltd. by ROHTO Jul 20, 2021 Products/BusinessR&D Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis See Past News Relese News Release RSS IR News See All IR News IR News RSS R&D Release Sep 30, 2022 Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan Mar 28, 2022 Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202" Sep 7, 2021 Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information Jul 20, 2021 Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis Jun 30, 2021 We evaluated the performance of rapid test kits for coronavirus (SARS-CoV-2) antigens using laboratory samples. Jun 15, 2021 Initiation of Phase II Clinical Trial for Regenerative Medical Products Using Allogeneic Mesenchymal Stem Cells for Severe COVID-19 Pneumonia Patients Apr 14, 2021 Licensing Agreement with BioMimetics Sympathies for COVID-19 Treatment Candidate and Establishment of Research Organization 'RB⁺' to Uncover Novel Drug Targets from Regenerative Medicine Research Mar 23, 2021 Announcement Regarding Acquisition of Olympus RMS Corporation's Stock (Transfer Agreement) Mar 8, 2021 Announcement: Commencement of Domestic Phase II Clinical Trial of Janus Kinase Inhibitor "ROH-201" Dec 12, 2019 Announcement of Licensing Agreement for Ophthalmic Treatment "DW-1001" Sep 4, 2019 Establishment of ROHTO Advanced Research Hong Kong Limited as a Hub for Cutting-edge Research in Hong Kong See Past R&D Release R&D News RSS